CClinicalTrials.gg
CompletedNCT02079350Updated Mar 5, 2014

Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

An observational study in Patients Undergoing Liver Transplantation, sponsored by Turkiye Yuksek Ihtisas Education and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-03-05.

Sponsored by Turkiye Yuksek Ihtisas Education and Research Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
36
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

02

Conditions studied

  • Patients Undergoing Liver Transplantation
03

In context

Lead sponsor

Turkiye Yuksek Ihtisas Education and Research Hospital is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients undergoing living donor liver transplantation

Inclusion criteria

-Normal kidney function

Exclusion criteria

Exclusion Criteria:

  • anormal kidney function
  • cadaveric transplantation
  • emergency operation
  • patients less than 18 years old
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
36 participants (actual)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • %4 Gelofusine

    patients administered %4 Gelofusine during liver transplantation

    Drug: %6 HES and %4 Gelofusine

  • %6 HES

    patients administered %6 HES during liver transplantation

    Drug: %6 HES and %4 Gelofusine

Interventions

  • Drug%6 HES and %4 Gelofusine
06

What researchers measure

Primary outcomes

  1. renal dysfunction

    Time frame: 1 month

Secondary outcomes

  1. mortality

    Time frame: 1 month

07

Study locations

1 site
  • Turkey Yuksek Ihtisas Education and Research Hospital, Anesthesiology Clinic
    Ankara, 06550, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02079350
Lead sponsor
Turkiye Yuksek Ihtisas Education and Research Hospital
Responsible party
aslı demir (Associated professor, Turkiye Yuksek Ihtisas Education and Research Hospital) — Principal investigator
First posted
Mar 5, 2014
Start date
Jan 2011
Primary completion
Nov 2013
Completion
Dec 2013
Last update
Mar 5, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion